Individual results vary depending on treatment type, dose, and patient factors
The TRIUMPH-4 Phase 3 trial in obesity with knee osteoarthritis (Bays et al., NEJM 2025) reported 28.7% mean weight loss at 68 weeks at the 12 mg dose, plus a 75.8% reduction in WOMAC knee pain scores
doi: 10.1097/BOR.0000000000000011 14 HendersonBBitenskyLChayenJ
Get recommendations, tips, updates, promotions and more
Brain-Gut Axis Given its effects on the gastrointestinal tract, researchers are also looking at how BPC-157 may influence the gut-brain axis, a complex communication network between the gut and the brain that is thought to be involved in a variety of neurological and psychological conditions, including anxiety and depression
"They have to be markedly different to their natural form - which is tricky with peptides." Without a patent, he says, companies risk pouring money into a product with little financial protection